Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06320379 · ClinicalTrials.gov registry record · NA

Zypan Functional Dyspepsia

A NA study of Dyspepsia, sponsored by National University of Natural Medicine.

Recruiting
Registry status
NA
Development phase
64
Enrollment target
1
Study location

NCT06320379: Recruiting NA study of Dyspepsia, sponsored by National University of Natural Medicine.

NCT06320379 is a NA study of Dyspepsia that is actively recruiting participants, run by National University of Natural Medicine. The registered enrollment target is 64 participants, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06320379, a NA study of Dyspepsia, is actively recruiting participants, sponsored by National University of Natural Medicine.

RECRUITING
Registry status
NA
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Zypan
  • DIETARY_SUPPLEMENT Placebo Comparator

Study Locations (1)

Oregon

  • Helfgott Research Institute - Portland

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2023-03-15
Est. Completion 2024-12-31
Phase NA

What NCT06320379 shows while recruiting

NCT06320379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 71-participant average among 11 other Dyspepsia trials with a reported enrollment target (10% lower).

The record links to 1 condition, with Dyspepsia appearing as the primary indexed condition, and to 2 interventions - of which Zypan is the first listed.

NCT06320379 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT06320379 about?

NCT06320379 is a clinical study titled "Zypan Functional Dyspepsia". The purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.

What is the current status of trial NCT06320379?

This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2023-03-15. Estimated completion is 2024-12-31.

What conditions does trial NCT06320379 study?

This clinical trial studies the following conditions: Dyspepsia.

What interventions are being tested in trial NCT06320379?

The interventions under investigation include: Zypan (DIETARY_SUPPLEMENT), Placebo Comparator (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06320379?

This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06320379 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dyspepsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06320379's enrollment target sits among peer trials

64 6th of 11 higher than 6 of 11 other Dyspepsia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dyspepsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06320379, the US trial registry maintained by the National Library of Medicine. NCT06320379 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.